semaglutide arrhythmia Multiple GLP-1 drugs linked to lower AFib risk Semaglutide Safety with Atrial Fibrillation:

In February 2026, the FDA restricted GLP-1 APIs in non-approved compounded products, tightening enforcement in one area while, at the same time, Kennedys announcement committed to loosening access across 14 others

Together, these episodes explore how GLP-1 medications work, who theyre designed for, their potential benefits and risks, what were seeing both in practice and in the broader population, what the science says, and what active people need to know

Additionally, individuals with a history of heart disease, high blood pressure, or diabetes should be particularly vigilant about any new or unusual chest pain

It is important documentation when conducting RAC and MAC reviews

And even with the most advanced methods, researchers still cannot identify a specific genetic cause in most people on the spectrum

The medication handles the biology, but lifestyle habits and emotional triggers still play a significant role